/stocks — the workspaceLOADING
All MOLN SEC filings, by type → · Earnings date & implied move · Search inside filings
MOLECULAR PARTNERS AG (MOLN) is a biological products, (no diagnostic substances) company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind MOLN’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has MOLN been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as MOLN tagged it, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on MOLN plus an auto-SWOT — built from MOLN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate MOLN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from MOLN's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentMOLN files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because MOLN has not filed annual figures yet. That is a statement about the read, not about MOLN’s value. The page rebuilds daily.
Every refusal recorded for MOLN → · How often we decline, and why →
No lawmaker has disclosed a trade in MOLN under the STOCK Act.
No tracked institution reported a position in MOLN in the latest 13F round.
No open-market Form 4 buys or sells reported for MOLN in the last ~6 months.
2 of the 2 checks that ran found nothing new for MOLN. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Zurich-Schlieren, Switzerland
Source: the cover page of MOLECULAR PARTNERS AG’s 20-F filed 2026-03-12, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works